The strength of MMV’s product development partnership model and rigorous portfolio management make MMV a highly cost-effective and productive R&D organization. Below you will find all you need to know about working with MMV.
Submission deadline is Friday, 23 March, 2018.
Subscribe to our e-newsletter to keep up with our work and to be informed of future calls for proposals.
TPPs & TCPs
MMV's Target Product Profiles & Target Candidate Profiles highlight the needs in designing the next generation of medicines for malaria control and eradication. They explain the ideal and minimally acceptable characteristics needed for clinical candidate molecules (TCPs) and combination medicines (TPPs).
- Description of roles [PDF: 30Kb, 2 pages]
- Development of combination therapies for the treatment of uncomplicated P. falciparum malaria [PDF: 203Kb, 15 pages]
- Strategy for the selection and early development of combination drugs for the treatment of uncomplicated P. falciparum malaria [PDF: 120Kb, 9 pages]
The frontrunner templates are an aid for the project team to evaluate frontrunner compounds against the criteria associated with the next project milestone. They allow the team to clearly see the breadth and level of expectations regarding the assays and data required.